Jason Rhodes, M.B.A.
Jason Rhodes is a partner at Atlas Venture and focuses on the creation, development, and business strategy of novel therapeutics companies. He is the chairman and was the founding CEO of Generation Bio, and is the executive chairman and acting CEO of Disarm Therapeutics. He sits on the boards of Atlas portfolio companies Replimune (NASDAQ: REPL), Accent Therapeutics, Gemini Therapeutics, Bicycle Therapeutics, and several seed-stage companies. Prior to joining Atlas, Jason was president of Epizyme (NASDAQ: EPZM), which he joined when it was a private, research-stage company and helped lead through a series of successful partnerships and an IPO in 2013. Prior to that Jason led business development at Alnylam (NASDAQ: ALNY), and he was a founder and partner with Fidelity Biosciences before that. Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania. He is a member of the advisory board of the Harvard Institute for RNA Medicine, the investment advisory board of the Blavatnik fund at Yale, and the Berklee College of Music Presidential Advisory Council.